Завершено
Фаза III
Беларусь
EG12014 · EirGenix, Inc., Taiwan, Китайская Республика
A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer